Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Atyr PHARMA INC (NASDAQ:ATYR) have received a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $18.60.

A number of brokerages have recently commented on ATYR. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target on the stock.

Atyr PHARMA Stock Performance

Shares of Atyr PHARMA stock opened at $3.97 on Friday. Atyr PHARMA has a 52 week low of $1.42 and a 52 week high of $4.66. The company has a market capitalization of $333.25 million, a PE ratio of -4.22 and a beta of 0.98. The stock’s fifty day moving average is $3.65 and its two-hundred day moving average is $3.06. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, analysts expect that Atyr PHARMA will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. bought a new stake in Atyr PHARMA during the fourth quarter valued at about $201,000. Alpine Global Management LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $63,000. Woodline Partners LP purchased a new position in shares of Atyr PHARMA in the 4th quarter worth approximately $6,092,000. Squarepoint Ops LLC bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $96,000. Finally, Two Sigma Advisers LP purchased a new stake in Atyr PHARMA during the fourth quarter valued at approximately $44,000. 61.72% of the stock is owned by institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.